WE have recently demonstrated (Coombs et al., 1976) that there is good agreement between mutagenicity (as measured by Ames' test with Salmonella typhimurium TA 100 with microsomal activation) and carcinogenicity among 34 closely related polycyclic compounds belonging to the cyclopenta[a]phenanthrene and chrysene series, all synthesized and tested in these laboratories. Carcinogenicity was assayed in all cases by the production of skin tumours on application of a solution of the compound twice weekly to the shaved dorsal skin of TO mice for one year, followed by observation for a second year. Of these 34 compounds, the 19 carcinogens were without exception also mutagenic; as expected, the majority of the non-carcinogens were not. However, there were 6 compounds which were mutagenic but not carcinogenic (C-M+) in our test system. On the widely held theory that tumour initiation is a mutagenic event, it seemed possible that these compounds might be incomplete carcinogens, i.e. initiators which lack promoting activity. In order to test this idea, 2 or these compounds, (I) and (IV) in Fig. 1 , together with 2 representative carcinogen/mutagens (C+M+), (III) and (V), and a noncarcinogen/non-mutagen (C-M-) (II), have been retested for tumour production in the 2-stage system, using croton oil as the promoting agent.
Three-month-old albino TO mice were assigned to 13 groups by a formal randomisation procedure, each group consisting of 10 male and 10 females. hydro-1 1-methylchrysen-l-one. (Coombs, 1966; Coombs et al., 1970) . carcinogen/non-mutagen (II), and again survival of these animals was similar to that of the control groups (11 and 12). The time of first appearance ofthe skin tumours induced by compounds (III) and (V) is depicted in Fig. 2 . At this initiating dose (400 ,g) only a few tumours were observed when the mice were treated subsequently with toluene alone, and these tumours appeared late. When promotion with croton oil was used, the tumour incidence was 90% with both (III) and (V), and the latent periods of the tumours were similar to those of the skin tumours produced by repeated treatment with (III) (Group 13) under the conditions previously used. However, all the tumours examined histologically from Group 13 were carcinomas, as judged by the criterion of tumour invasion of the panniculus carnosus muscle, whereas tumours from the croton-oiltreated animals (Groups 4 and 10) consisted 60% carcinomas and 40% papillomas.
Thus, it appears that the mutagens (I) and (IV) are not initiating agents, at least under conditions where the carcinogens (III) and (V) are very active. Although we have no information on the relative extents to which these compounds are metabolized by mouse shin cells to reactive metabolites that bind to DNA in vivo, the same initiating dose was used because compounds (I) and (III)-(V) give comparable numbers of revertants in Ames' test (Coombs et al., 1976) . Moreover, it is known that compounds (I) and (III) are metabolized to a similar extent by rat liver microsomes in vitro, and bind to a similar extent to DNA added to these incubations (Coombs et al., 1975) . There is no reason to suppose that (I) and (IV) are not representative of the 4 other mutagens/non-carcinogens (C-M+) in the original collection. These 34 closely related compounds may be classified into 3 sets: C+M+, C-M+ and C-M-. No member of the fourth possible combination (C+M-) has been observed by us, although such compounds have been reported and discussed by others (McCann and Ames, 1976; Purchase et al., 1976) .
C-M+ compounds such as (I) are capable of metabolic activation to active species that bind covalently to DNA in vitro and cause mutation in bacteria. Presumably in the animal cell other factors operate to prevent these active metabolites from damaging the genetic material.
